Frankfurt - Delayed Quote EUR

Madrigal Pharmaceuticals, Inc. (YDO1.F)

272.00

+7.50

+(2.84%)

At close: 9:55:02 PM GMT+2

Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025

CONSHOHOCKEN, Pa., April 18, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), announced today that it will release its first-quarter 2025 financial results on Thursday, May 1, 2025, prior to the open of the U.S. financial markets. Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Comp

GlobeNewswire 5 days ago

MDGL
Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D., Appointed Chief Medical Officer

Dr. Taub’s pioneering research in academia and industry led to the first FDA-approved therapy for patients with MASHCONSHOHOCKEN, Pa., April 16, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that Rebecca Taub, M.D., the company's founder, Chief Medical Officer, and President of Research & Development (R&D), will transition to

GlobeNewswire 7 days ago

MDGL
Is Madrigal Pharmaceuticals (MDGL) The Most Expensive Stock Insiders Are Dumping In March?

We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take a look at where Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) stands against other most expensive stocks insiders are dumping in March. After being in the green for a few trading sessions, the broader market […]

Insider Monkey 25 days ago

MDGL

COMP
Exploring 3 High Growth Tech Stocks in the US Market

In the last week, the United States market has stayed flat, but it is up 7.8% over the past year with earnings forecast to grow by 14% annually. In this context of steady growth and positive projections, identifying high growth tech stocks involves looking for companies with innovative products and strong potential to capitalize on emerging trends within the tech sector.

Simply Wall St. 26 days ago

VNET

EXLS

MDGL
Madrigal Pharmaceuticals (MDGL): Among the Best Biotech Stocks to Buy According to Billionaires

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) stands against other best biotech stocks. Although biotech stocks had a “challenging” year in 2024, JPMorgan believes that some of the industry’s companies […]

Insider Monkey last month

MDGL
Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors

Fred Craves, Ph.D. to retire from Madrigal’s Board of Directors in July 2025 CONSHOHOCKEN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has appointed Jacqualyn (“Jackie”) Fouse, Ph.D. to its Board of Directors. Fred Craves, Ph.D. is retiring from the Board in July 2025. Julian Baker, Chairman of the Board of

GlobeNewswire last month

MDGL
Goldman Sachs Says It’s Time to Pull the Trigger on Healthcare Stocks — Here Are 2 Names to Pounce on Now

The markets have been volatile recently as economic uncertainty and tariff threats have rattled investors. Yet, despite the concerns, Goldman Sachs’ chief US equity strategist David Kostin sees reason for long-term optimism – and makes some concrete recommendations about where investors should put their funds to cash in. Simply put, Kostin believes that healthcare stocks are the way to go in 2025. Healthcare makes up more than 17% of the total US economy, and it has a defensive tilt – even if ti

TipRanks last month

MDGL

PCVX
Madrigal Pharmaceuticals price target raised to $239 from $154 at BofA

BofA raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $239 from $154 and keeps an Underperform rating on the shares. The Q4 updates, which included “favorable” two-year OLE data, were “positive” and Rezdiffra’s launch has been “robust” despite the firm’s initial concerns, the analyst tells investors. However, while the firm recognizes room for further near-term sales upside, the extent to which this has already been priced into shares and the “aggressive expansion” of 2025 an

TipRanks last month

MDGL
We're Not Worried About Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Simply Wall St. last month

MDGL
High Growth Tech Stocks In US For February 2025

Over the last 7 days, the United States market has experienced a 3.6% drop, yet it remains up by 17% over the past year with earnings forecasted to grow by 14% annually. In this context of fluctuating short-term movements and promising long-term growth prospects, identifying high-growth tech stocks involves focusing on companies that demonstrate strong innovation potential and adaptability in an ever-evolving technological landscape.

Simply Wall St. last month

MDGL

WK

INTU
Madrigal Pharmaceuticals Inc (MDGL) Q4 2024 Earnings Call Highlights: Strong Sales Growth and ...

Madrigal Pharmaceuticals Inc (MDGL) reports robust financial performance with significant milestones in Rezdiffra's launch and market penetration.

GuruFocus.com last month

MDGL
Q4 2024 Madrigal Pharmaceuticals Inc Earnings Call

Q4 2024 Madrigal Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents last month

MDGL
Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis

On Wednesday, Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) reported two-year results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of Rezdiffra (resmetirom). Patients treated with Rezdiffra achieved marked reductions in liver stiffness, a surrogate for fibrosis, measured by vibration-controlled transient elastography (VCTE). The Phase 3 MAESTRO-NAFLD-1 trial of Rezdiffra included an open-label active treatment arm of patients with compensated MASH

Benzinga last month

MDGL
Madrigal Q4 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up

MDGL stock is rising as it reports better-than-expected fourth-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.

Zacks last month

MDGL
Why Madrigal Pharmaceuticals Stock Is Soaring Today

Shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday. The big gain came after the small biopharmaceutical company announced its fourth-quarter and full-year 2024 results before the market opened. Madrigal reported fourth-quarter revenue of $103.3 million, all of which stemmed from sales of Rezdiffra, the first drug approved for treating metabolic dysfunction-associated steatohepatitis (MASH).

Motley Fool last month

MDGL
Madrigal: Q4 Earnings Snapshot

WEST CONSHOHOCKEN, Pa. AP) — Madrigal Pharmaceuticals Inc. MDGL) on Wednesday reported a loss of $59.4 million in its fourth quarter.

Associated Press Finance last month

MDGL
Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

Fourth-quarter and full-year 2024 Rezdiffra net sales of $103.3 million and $180.1 million, respectivelyAs of year-end 2024, more than 11,800 patients on Rezdiffra Reports cash, cash equivalents, restricted cash and marketable securities of $931.3 million at December 31, 2024Announces new two-year data for the active-treatment open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial Company to host conference call today, February 26, 2025, at 8 a.m. EST CONSHOHOCKEN,

GlobeNewswire last month

MDGL
Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

Patients achieved a mean 6.7 kPa reduction in liver stiffness as measured by vibration-controlled transient elastography (VCTE); this represents the largest reduction in liver stiffness reported in a compensated MASH cirrhosis patient population 51% of patients achieved a ≥25% reduction in liver stiffness; a reduction of this magnitude has been associated with reduced progression to end-stage liver diseaseCompany to review topline data during its fourth-quarter and full-year 2024 financial resul

GlobeNewswire last month

MDGL
Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference

CONSHOHOCKEN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the 45th Annual TD Cowen Health Care Conference on Tuesday, March 4, 2025 at 11:10 A.M. ET. The presentation will be webcast live and may be accessed here or by visiting Madrigal’s Investor Relations Events page. A replay of the webcast will be available after the event. About Madrigal PharmaceuticalsMadrigal Pharmaceuticals, Inc. (Nasdaq: MDGL)

GlobeNewswire last month

MDGL
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025

CONSHOHOCKEN, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its fourth-quarter and full-year 2024 financial results on Wednesday, Feb. 26, 2025, prior to the open of the U.S. financial markets. Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results. The live webcast may be accessed at the Investor Relations section of the M

GlobeNewswire 2 months ago

MDGL

Performance Overview

Return	YDO1.F	S&P 500 (^GSPC)
YTD	-8.39%	-8.60%
1-Year	+34.32%	+6.02%
3-Year	+291.37%	+25.85%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Madrigal Pharmaceuticals, Inc. (YDO1.F)

Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025

Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D., Appointed Chief Medical Officer

Is Madrigal Pharmaceuticals (MDGL) The Most Expensive Stock Insiders Are Dumping In March?

Exploring 3 High Growth Tech Stocks in the US Market

Madrigal Pharmaceuticals (MDGL): Among the Best Biotech Stocks to Buy According to Billionaires

Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors

Goldman Sachs Says It’s Time to Pull the Trigger on Healthcare Stocks — Here Are 2 Names to Pounce on Now

Madrigal Pharmaceuticals price target raised to $239 from $154 at BofA

We're Not Worried About Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn

High Growth Tech Stocks In US For February 2025

Madrigal Pharmaceuticals Inc (MDGL) Q4 2024 Earnings Call Highlights: Strong Sales Growth and ...

Q4 2024 Madrigal Pharmaceuticals Inc Earnings Call

Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis

Madrigal Q4 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up

Why Madrigal Pharmaceuticals Stock Is Soaring Today

Madrigal: Q4 Earnings Snapshot

Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference

Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025

Performance Overview